Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease:A review of the literature

作     者：Thais Gagno Grillo Caroline Ferreira da Silva Mazeto Pupo Silveira Ana Elisa Valencise Quaglio Renata de Medeiros Dutra Julio Pinheiro Baima Silmeia Garcia Zanati Bazan Ligia Yukie Sassaki 

作者机构：Department of Internal MedicineMedical SchoolSão Paulo State UniversityBotucatuBotucatu 18618686Brazil Department of Biophysics and PharmacologyInstitute of BiosciencesSão Paulo State UniversityBotucatuBotucatu 18618689Brazil 

出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志（英文版）（电子版）)

年 卷 期：2023年第15卷第5期

页      面：217-228页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Tumor necrosis factor inhibitors Inflammatory bowel disease Heart failure Adverse event TNFαreceptor 

摘      要：Tumor necrosis factor inhibitors(anti-TNFs)are widely used therapies for the treatment of inflammatory bowel diseases(IBD);however,their administration is not *** failure(HF),although rare,is a potential adverse event related to administration of these ***,the exact mechanism of development of HF remains ***αis found in both healthy and damaged *** effects are concentration-and receptor-dependent,promoting either cardio-protection or cardiomyocyte *** rat models with TNFαreceptor knockout showed increased survival rates,less reactive oxygen species formation,and improved diastolic left ventricle ***,clinical trials employing anti-TNF therapy to treat HF had disappointing results,suggesting abolishment of the cardioprotective properties of TNFα,making cardiomyocytes susceptible to apoptosis and ***,patients with IBD who have risk factors should be screened for HF before initiating anti-TNF *** review aims to discuss adverse events associated with the administration of anti-TNF therapy,with a focus on HF,and propose some approaches to avoid cardiac adverse events in patients with IBD.